Abstract
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Current Cancer Therapy Reviews
Title: Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Volume: 4 Issue: 4
Author(s): Paul J. Cozzi, John Kearsley and Yong Li
Affiliation:
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Abstract: Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Export Options
About this article
Cite this article as:
Cozzi J. Paul, Kearsley John and Li Yong, Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413371
DOI https://dx.doi.org/10.2174/157339408786413371 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights Into Nicotinic Receptor Signaling in Nicotine Addiction: Implications for Prevention and Treatment
Current Neuropharmacology Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry IGF-1 Gene Therapy as a Potentially Useful Therapy for Spontaneous Prolactinomas in Senile Rats
Current Gene Therapy Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Cytotoxic Activity and Inhibition of Tumor Cell Invasion by Derivatives of a Chemically Modified Tetracycline CMT-3 (COL-3)
Current Medicinal Chemistry Insulin-Like Growth Factor-1, a Potential Predicative Biomarker for Postoperative Delirium Among Elderly Patients with Open Abdominal Surgery
Current Pharmaceutical Design Cytokine and Immune System Abnormalities in Fibromyalgia and Other Central Sensitivity Syndromes
Current Rheumatology Reviews Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Diphenylpentane Skeleton as a Multi-Template for Steroid Skeleton- Recognizing Receptors/Enzymes
Mini-Reviews in Medicinal Chemistry Recent Advances and Patents on Solid Lipid Nanoparticles
Recent Patents on Drug Delivery & Formulation The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Subject Index To Volume 2
Current Immunology Reviews (Discontinued) Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Blending of Polyethylenimine with a Cationic Polyurethane Greatly Enhances Both DNA Delivery Efficacy and Reduces the Overall Cytotoxicity
Current Pharmaceutical Biotechnology Bioinformatics Tools for Mass Spectrometry-Based High-Throughput Quantitative Proteomics Platforms
Current Proteomics Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets